Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000083.xml
Synlett 2019; 30(07): 860-862
DOI: 10.1055/s-0037-1611759
DOI: 10.1055/s-0037-1611759
letter
A Concise Enantioselective Synthesis of (S)-Preclamol via Asymmetric Catalytic Negishi Cross-Coupling Reaction
We are thankful to the National Key Technology Research and Development Program of China (No. 2017YFD0201404) for the financial support.Further Information
Publication History
Received: 21 February 2019
Accepted after revision: 21 February 2019
Publication Date:
26 March 2019 (online)
◊ These authors contributed equally to this work and should be considered as co-first authors
Abstract
A novel, concise, and efficient enantioselective synthesis of (S)-preclamol (87% ee, 51% total yield) has been developed. The key steps of this synthetic approach included cobalt-catalyzed asymmetric catalytic cross-coupling of α-bromo ester with arylzinc and the reduction of chiral ester to diol with a tertiary carbon atom. Moreover, it was demonstrated that our enantioselective Negishi cross-coupling was a powerful tool to construct stereogenic benzylmethyl center in chiral drugs on a gram scale.
Key words
(S)-preclamol - enantioselective Negishi cross-coupling - cobalt - asymmetric synthesis - chiral drugSupporting Information
- Supporting information for this article is available online at https://doi.org/10.1055/s-0037-1611759.
- Supporting Information
-
References and Notes
- 1 Hjorth S, Carlsson A, Wikstroem H, Lindberg P, Sanchez D, Hacksell U, Arvidsson LE, Svensson U, Nilsson JL. G. Life Sci. 1981; 28: 1225
- 2 Hjorth S, Carlsson A, Clark D, Svensson K, Wikstroem H, Sanchez D, Lindberg P, Hacksell U, Arvidsson LE, Johansson A, Nilsson JL. G. Psychopharmacology 1983; 81: 89
- 3 Tamminga CA, Cascella NG, Lahti RA, Lindberg M, Carlsson A. J. Neural Transm.: Gen. Sect. 1992; 88: 165
- 4 Lahti AC, Weiler MA, Corey PK, Lahti RA, Carlsson A, Tamminga CA. Biol. Psychiatry 1998; 43: 2
- 5 Metman LV, Sethy VH, Roberts JR, Bravi D, Hoff JI, Mouradian MM, Chase TN. Mov. Disord. 1994; 9: 577
- 6 Liljefors T, Wikstroem H. J. Med. Chem. 1986; 29: 1896
- 7 Liljefors T, Boegesoe KP, Hyttel J, Wikstroem H, Svensson K, Carlsson A. J. Med. Chem. 1990; 33: 1015
- 8 Lane JR, Powney B, Wise A, Rees S, Milligan G. Mol. Pharmacol. 2007; 71: 1349
- 9 Jordan S, Johnson Janelle L, Regardie K, Chen R, Koprivica V, Tadori Y, Kambayashi J, Kitagawa H, Kikuchi T. Prog. Neuropsychopharmacol Biol. Psychiatry 2007; 31: 348
- 10 Amat M, Canto M, Llor N, Escolano C, Molins E, Espinosa E, Bosch J. J. Org. Chem. 2002; 67: 5343
- 11 Thorberg SO, Gawell L, Csoeregh I, Nilsson JL. G. Tetrahedron 1985; 41: 129
- 12 Arnold W, Daly JJ, Imhof R, Kyburz E. Tetrahedron Lett. 1983; 24: 343
- 13 Zhang S.-J, Sun W.-W, Yu Q.-Y, Cao P, Dong X.-P, Wu B. Tetrahedron Lett. 2017; 58: 606
- 14 Schafer P, Palacin T, Sidera M, Fletcher SP. Nat. Commun. 2017; 8: 15762
- 15 Yang X.-H, Yue H.-T, Yu N, Li Y.-P, Xie J.-H, Zhou Q.-L. Chem. Sci. 2017; 8: 1811
- 16 Hamilton JY, Sarlah D, Carreira EM. Angew. Chem. Int. Ed. 2015; 54: 7644
- 17 Jia T, Cao P, Wang B, Lou Y, Yin X, Wang M, Liao J. J. Am. Chem. Soc. 2015; 137: 13760
- 18 Zheng Y, Yue B.-B, Wei K, Yang Y.-R. Org. Lett. 2018; 20: 8035
- 19a Arp FO, Fu GC. J. Am. Chem. Soc. 2005; 127: 10482
- 19b Son S, Fu GC. J. Am. Chem. Soc. 2008; 130: 2756
- 19c Binder JT, Cordier CJ, Fu GC. J. Am. Chem. Soc. 2012; 134: 17003
- 19d Choi J, Martín-Gago P, Fu GC. J. Am. Chem. Soc. 2014; 136: 12161
- 19e Liang YY, Fu GC. J. Am. Chem. Soc. 2014; 136: 5520
- 19f Schmidt J, Choi J, Liu AT, Slusarczyk M, Fu GC. Science 2016; 354: 1265
- 20 Liu F, Zhong J, Zhou Y, Gao Z, Walsh PJ, Wang X, Ma S, Hou S, Liu S, Wang M, Wang M, Bian Q. Chem. Eur. J. 2018; 24: 2059
- 21 McCann LC, Organ MG. Angew. Chem. Int. Ed. 2014; 53: 4386
- 22 The Experimental Procedures and Characterization Data for (S)-3 Magnesium turnings (1.46 g, 60 mmol) were placed in a two-neck 250 mL Schlenk flask equipped with funnel, and the flask was heated at 80 °C for 1 h under an argon atmosphere. After being cooled to room temperature, anhydrous THF (50 mL) and 1-bromo-3-methoxybenzene (1.87 g, 10 mmol) were added sequentially. The reaction was initiated by gently heating with a heat gun, and additional 1-bromo-3-methoxybenzene (7.48 g, 40 mmol) in THF (10 mL) was added dropwise. The resulting mixture was stirred and refluxed for 2 h. The concentration of prepared (3-methoxyphenyl)magnesium bromide was titrated with I2. ZnBr2 (10.12 g, 45 mmol) was placed in another 250 mL Schlenk flask and was heated at 100 °C for 1.5 h under an argon atmosphere. After being cooled to ambient temperature, anhydrous THF (68.8 mL) was added, and the resulting mixture was stirred for 10 min. The prepared (3-methoxyphenyl)magnesium bromide (30 mmol, 0.586 M in THF, 51.2 mL) was added via syringe over 25 min. The resulting mixture was stirred for 2 h at room temperature. Anhydrous cobalt(II) iodide (160 mg, 0.50 mmol) was placed in a separate 100 mL Schlenk tube and heated at 80 °C for 2 h in vacuo. After being cooled to room temperature under an argon atmosphere, anhydrous THF (10 mL) and L1 (330 mg, 0.60 mmol) in THF (5 mL) were added. The mixture was stirred for 2 h at room temperature, racemic dibenzyl 2-bromopentanedioate (1, 1.97 g, 5.0 mmol) was added via syringe. The resulting mixture was cooled to –25 °C, the suspension of (3-methoxyphenyl)zinc bromide (2, 25 mmol) was added dropwise over 30 min. After stirring at –25 °C for 24 h, the reaction was quenched with saturated NH4Cl solution (10 mL). The layers were separated, and the aqueous phase was extracted with Et2O (3 × 50 mL). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel chromatography (petroleum ether/dichloromethane, 1:2) to provide (S)-dibenzyl-2-(3-methoxyphenyl)pentanedioate (3, 1.94 g, 93% yield, 87% ee) as a colorless oil. The ee was determined by HPLC with a Daicel Chiralcel OD-H column (2% isopropanol in n-hexane, 1 mL/min, 220 nm, minor t R = 22.27 min (R), major t R = 25.49 min (S)). [α]D 23 + 24.6 (c 1.3, CHCl3). 1H NMR (300 MHz, CDCl3): δ = 7.34–7.18 (m, 11 H), 6.84–6.79 (m, 3 H), 5.15–5.04 (m, 4 H), 3.74 (s, 3 H), 3.64 (t, J = 7.4 Hz, 1 H), 2.45–2.33 (m, 1 H), 2.31 (t, J = 7.4 Hz, 2 H), 2.20–2.09 (m, 1 H).13C NMR (75 MHz, CDCl3): δ = 173.0, 172.6, 159.8, 139.5, 135.87, 135.80, 129.7, 128.5, 128.4, 128.2, 128.1, 127.9, 120.4, 113.5, 113.1, 66.5, 66.3, 55.1, 50.5, 31.8, 28.2. HRMS (ESI): m/z calcd for C26H27O5 [M + H]+419.1853; found: 419.1840.
- 23 Dai X, Strotman NA, Fu GC. J. Am. Chem. Soc. 2008; 130: 3302